ATYR PHARMA INC (ATYR:NASDAQ)
$0.8324 0.0824 (10.9867%)
Analysed ATYR PHARMA INC (ATYR:NASDAQ) News Sources
Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight
08-04-2026
yahoo.com
aTyr Pharma Spotlights Efzofitimod Phase 3 Learnings, Eyes Mid-April FDA Type C Meeting
12-03-2026
marketbeat.com
Atyr Pharma: Q4 Earnings Snapshot
05-03-2026
yahoo.com
aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update
05-03-2026
yahoo.com
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20-02-2026
yahoo.com
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
18-02-2026
yahoo.com
aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis
03-02-2026
yahoo.com
Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Deliver On Growth Plans?
11-01-2026
yahoo.com
aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference
10-11-2025
yahoo.com
Atyr Pharma: Q3 Earnings Snapshot
06-11-2025
yahoo.com
What is the current price of ATYR PHARMA INC (ATYR:NASDAQ)?
The current price of ATYR PHARMA INC (ATYR:NASDAQ) is $0.8324.
ATYR PHARMA INC (ATYR:NASDAQ) absolute price change since previous trading day?
The absolute price change of ATYR PHARMA INC (ATYR:NASDAQ) since the previous trading day is $0.0824.
ATYR PHARMA INC (ATYR:NASDAQ) percentage price change since previous trading day?
The percentage price change of ATYR PHARMA INC (ATYR:NASDAQ) since the previous trading day is 10.9867%.
What is the most recent average sentiment score for ATYR PHARMA INC (ATYR:NASDAQ)?
The most recent average sentiment score for ATYR PHARMA INC (ATYR:NASDAQ) is 69 out of 100.
What is the most recent average sentiment for ATYR PHARMA INC (ATYR:NASDAQ)?
The most recent sentiment for ATYR PHARMA INC (ATYR:NASDAQ) is .
SEC-8K** Filing Available For ATYR PHARMA INC (ATYR:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.